Discordance	O
in	O
pathology	B:C0807321
report	I:C0807321
after	O
central	O
pathology	I:C2347585
review	I:C2347585
:	O
Implications	O
for	O
breast	O
cancer	I:C0006142
adjuvant	O
treatment	I:C0677850
.	O

Discordance	O
in	O
pathology	O
report	I:C0807321
after	O
central	B:C2347585
pathology	I:C2347585
review	I:C2347585
:	O
Implications	O
for	O
breast	O
cancer	I:C0006142
adjuvant	O
treatment	I:C0677850
.	O

Discordance	O
in	O
pathology	O
report	I:C0807321
after	O
central	O
pathology	I:C2347585
review	I:C2347585
:	O
Implications	O
for	O
breast	B:C0006142
cancer	I:C0006142
adjuvant	O
treatment	I:C0677850
.	O

Discordance	O
in	O
pathology	O
report	I:C0807321
after	O
central	O
pathology	I:C2347585
review	I:C2347585
:	O
Implications	O
for	O
breast	O
cancer	I:C0006142
adjuvant	B:C0677850
treatment	I:C0677850
.	O

Pathological	O
predictive	B:C0683956
factors	I:C0683956
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	O
cancer	I:C0006142
adjuvant	O
therapy	I:C0677850
.	O

Pathological	O
predictive	O
factors	I:C0683956
are	O
the	O
most	O
important	O
markers	B:C0005516
when	O
selecting	O
early	O
breast	O
cancer	I:C0006142
adjuvant	O
therapy	I:C0677850
.	O

Pathological	O
predictive	O
factors	I:C0683956
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	B:C0006142
cancer	I:C0006142
adjuvant	O
therapy	I:C0677850
.	O

Pathological	O
predictive	O
factors	I:C0683956
are	O
the	O
most	O
important	O
markers	O
when	O
selecting	O
early	O
breast	O
cancer	I:C0006142
adjuvant	B:C0677850
therapy	I:C0677850
.	O

In	O
randomized	B:C0206034
clinical	I:C0206034
trials	I:C0206034
the	O
variability	O
in	O
pathology	O
report	I:C0807321
after	O
central	O
pathology	I:C2347585
review	I:C2347585
is	O
noteworthy	O
.	O

In	O
randomized	O
clinical	I:C0206034
trials	I:C0206034
the	O
variability	O
in	O
pathology	B:C0807321
report	I:C0807321
after	O
central	O
pathology	I:C2347585
review	I:C2347585
is	O
noteworthy	O
.	O

In	O
randomized	O
clinical	I:C0206034
trials	I:C0206034
the	O
variability	O
in	O
pathology	O
report	I:C0807321
after	O
central	B:C2347585
pathology	I:C2347585
review	I:C2347585
is	O
noteworthy	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	B:C0205276
and	O
central	O
histopathological	O
report	I:C0684224
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	O
and	O
central	B:C0205099
histopathological	O
report	I:C0684224
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter-rater	O
agreement	O
between	O
local	O
and	O
central	O
histopathological	B:C0684224
report	I:C0684224
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

A	O
retrospective	B:C0035363
analysis	I:C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	I:C1458155
tumors	I:C1458155
diagnosed	O
by	O
local	O
pathologists	I:C0334866
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	I:C0587487
of	O
European	O
Institute	I:C1708333
of	I:C1708333
Oncology	I:C1708333
.	O

A	O
retrospective	O
analysis	I:C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B:C1458155
cancer	I:C1458155
tumors	I:C1458155
diagnosed	O
by	O
local	O
pathologists	I:C0334866
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	I:C0587487
of	O
European	O
Institute	I:C1708333
of	I:C1708333
Oncology	I:C1708333
.	O

A	O
retrospective	O
analysis	I:C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	I:C1458155
tumors	I:C1458155
diagnosed	O
by	O
local	B:C0334866
pathologists	I:C0334866
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	I:C0587487
of	O
European	O
Institute	I:C1708333
of	I:C1708333
Oncology	I:C1708333
.	O

A	O
retrospective	O
analysis	I:C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	I:C1458155
tumors	I:C1458155
diagnosed	O
by	O
local	O
pathologists	I:C0334866
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	B:C0587487
Division	I:C0587487
of	O
European	O
Institute	I:C1708333
of	I:C1708333
Oncology	I:C1708333
.	O

A	O
retrospective	O
analysis	I:C0035363
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	O
cancer	I:C1458155
tumors	I:C1458155
diagnosed	O
by	O
local	O
pathologists	I:C0334866
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	O
Division	I:C0587487
of	O
European	B:C1708333
Institute	I:C1708333
of	I:C1708333
Oncology	I:C1708333
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	B:C0030664
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	I:C0019929
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	B:C0208804
,	O
grading	O
,	O
hormone	O
receptors	I:C0019929
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	B:C0441799
,	O
hormone	O
receptors	I:C0019929
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	B:C0019929
receptors	I:C0019929
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	I:C0019929
(	O
ER	B:C0034804
/	O
PgR	O
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	I:C0019929
(	O
ER	O
/	O
PgR	B:C0034833
)	O
and	O
HER2	O
/	I:C1512413
neu	I:C1512413
.	O

The	O
inter	O
-rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	O
pathology	I:C0030664
was	O
calculated	O
for	O
Ki-67	O
,	O
grading	O
,	O
hormone	O
receptors	I:C0019929
(	O
ER	O
/	O
PgR	O
)	O
and	O
HER2	B:C1512413
/	I:C1512413
neu	I:C1512413
.	O

The	O
Bland	B:C0242481
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	B:C0208804
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	B:C0034804
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	B:C0034833
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	B:C0034804
/	O
PgR	O
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	B:C0034833
and	O
HER2	O
.	O

The	O
Bland	O
-	I:C0242481
Altman	I:C0242481
plots	I:C0242481
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki-67	O
,	O
ER	O
and	O
PgR.	O
DR	O
was	O
calculated	O
for	O
ER	O
/	O
PgR	O
and	O
HER2	B:C0069515
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	B:C0444061
specimens	I:C0444061
from	O
10	O
Cancer	O
Centers	I:C1513817
were	O
reviewed	O
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	O
specimens	I:C0444061
from	O
10	O
Cancer	B:C1513817
Centers	I:C1513817
were	O
reviewed	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	B:C0034804
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	B:C0034833
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	B:C0208804
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	O
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	O
(	O
k0.612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0.686	O
)	O
,	O
PgR	O
(	O
k0.659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0.737	O
)	O
,	O
Ki-67	O
(	O
k0.609	O
;	O
95	O
%	O
CI	O
,	O
0.534-0.684	O
)	O
and	O
grading	B:C0441799
(	O
k0.669	O
;	O
95	O
%	O
CI	O
,	O
0.569-0.769	O
)	O
.	O

Moderate	O
agreement	O
was	O
found	O
for	O
HER2	B:C0069515
(	O
k0.546	O
;	O
95	O
%	O
CI	O
,	O
0444-0.649	O
)	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	B:C0069515
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	B:C0034804
/	O
PgR	O
.	O

DR	O
was	O
9.5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31.7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	O
and	O
26.2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12.5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	O
/	O
PgR	B:C0034833
.	O

According	O
to	O
changes	O
in	O
Her2	B:C0069515
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	B:C0034804
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	B:C0034833
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	O
were	O
respectively	O
modified	O
.	O

According	O
to	O
changes	O
in	O
Her2	O
and	O
ER	O
/	O
PgR	O
status	O
,	O
23	O
(	O
12.2	O
%	O
)	O
and	O
33	O
(	O
17.6	O
%	O
)	O
systemic	O
prescription	B:C0033080
were	O
respectively	O
modified	O
.	O

In	O
our	O
retrospective	B:C0035363
analysis	I:C0035363
,	O
central	O
pathological	I:C2347585
review	I:C2347585
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	O
-	O
making	O
process	O
in	O
early	O
breast	O
cancer	I:C0006142
,	O
as	O
shown	O
in	O
clinical	O
trials	I:C0008976
.	O

In	O
our	O
retrospective	O
analysis	I:C0035363
,	O
central	B:C2347585
pathological	I:C2347585
review	I:C2347585
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	O
-	O
making	O
process	O
in	O
early	O
breast	O
cancer	I:C0006142
,	O
as	O
shown	O
in	O
clinical	O
trials	I:C0008976
.	O

In	O
our	O
retrospective	O
analysis	I:C0035363
,	O
central	O
pathological	I:C2347585
review	I:C2347585
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	O
-	O
making	O
process	O
in	O
early	O
breast	B:C0006142
cancer	I:C0006142
,	O
as	O
shown	O
in	O
clinical	O
trials	I:C0008976
.	O

In	O
our	O
retrospective	O
analysis	I:C0035363
,	O
central	O
pathological	I:C2347585
review	I:C2347585
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	O
-	O
making	O
process	O
in	O
early	O
breast	O
cancer	I:C0006142
,	O
as	O
shown	O
in	O
clinical	B:C0008976
trials	I:C0008976
.	O

